靶向表皮生长因子受体免疫PET显像剂研究进展  

Research progress on immune PET imaging agents targeting epidermal growth factor receptors

作　　者：张晓君 徐万帮[2] 唐刚华(审校) ZHANG Xiaojun;XU Wanbang;TANG Ganghua(GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals,Department of Nuclear Medicine,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Department of Traditional Chinese Medicine,Guangdong Institute for Drug Control)

机构地区：[1]广东省药监局放射性药物质量控制与评价重点实验室,南方医科大学南方医院核医学科,广州510515 [2]广东省药品检验所中药室

出　　处：《国际医学放射学杂志》2023年第5期567-572,共6页International Journal of Medical Radiology

基　　金：国家自然科学基金重点研发计划(91949121);广东省基础与应用基础研究基金项目(2022A1515010072)。

摘　　要：表皮生长因子受体(EGFR)在癌症的发生、发展、迁移及新生血管形成中发挥着重要作用,在多种恶性肿瘤中存在过表达。靶向EGFR的免疫正电子发射体层成像(PET)结合了单克隆抗体的高靶向性及PET显像的高敏感度,可定量、无创地监测体内EGFR靶点的表达,从而评估肿瘤靶向治疗的效果,有助于肿瘤病人的个体化治疗,并指导抗癌药物的研发。就靶向EGFR免疫PET显像剂的最新研究进展及临床应用进行综述。Epidermal growth factor receptor(EGFR)is overexpressed in multiple malignant tumors,significantly regulating cancer occurence,progression,migration,and neovascularization.By combining the high specificity of monoclonal antibodies and sensitivity of PET imaging,EGFR-targeted immuno-positron emission tomography(PET)quantitatively and non-invasively monitors the expression of EGFR target in vivo and evaluates the therapeutic effect of tumor-targeted therapy,contributing to individualized treatment and guiding anti-cancer drug development.This article aimed to review the research progress and clinical applications of EGFR-targeted immuno-PET imaging agents.

关 键 词：免疫正电子发射体层成像 显像剂 表皮生长因子受体 分子成像 

分 类 号：R73[医药卫生—肿瘤] R817[医药卫生—临床医学]